ImmunoCellular Therapeutics (NYSE: IMUC) reported Q3 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06).

Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: "We believe that the progress we made in the third quarter was significant. Our ICT-107 phase III planning is well underway, and we anticipate being prepared to initiate that program in mid-2015. We are looking forward to presenting updated data from the ICT-107 phase II trial at the Society for Neuro-oncology (SNO) meeting in Miami on November 14th. We have also made significant progress in advancing our ICT-121 and ICT 140 programs. Additional clinical sites are being added to the ICT-121 phase I trial, and enrollment of patients with recurrent glioblastoma should increase shortly. We plan to complete enrollment of 20 patients in this trial by the second quarter of 2015. Plans are progressing well to initiate the exploratory phase II ICT-140 trial, which is designed to enroll 56 patients with ovarian cancer and utilize historical controls as the comparator in the trial."

Mr. Gengos added: "A highlight of the third quarter was the important licensing agreement we established with Caltech, which represents an opportunity to expand and diversify our immunotherapy platform. Immune-based approaches to treating cancer continue to be promising and we think that the Caltech technology will be highly complementary to our current dendritic cell-based efforts. Our goal is to utilize this technology to expand and enrich our pipeline of immuno-oncology product candidates. This collaboration represents progress toward our goal of building a leading cancer immunotherapy company based on multiple approaches to immune system stimulation."

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.